EFAVIRENZ | N021360 | BRISTOL MYERS SQUIBB CO
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2015-11-16 | Terminated 2016-01-11 | — | |
Merck, Sharp & Dohme Corp. et al v. Teva Pharmaceuticals USA, Inc. et al 2 patentsANDA 091215efavirenz | S.D.N.Y. | 2010-03-09 | Terminated 2013-06-05 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizens Petition from Lachman Consultant Services, Inc. FDA-2005-P-0515 · 7 docket documents Lachman Consultant Services, Inc. submitted this petition under Section 505(j)(2)(C) requesting that the FDA declare Efavirenz Tablets for Oral Suspension in 50 mg, 100 mg, and 200 mg strengths suitable for submission in an ANDA, with the reference-listed drug being Sustiva efavirenz Capsules 200 mg | Other | 2010-01-21 | Withdrawn | Lachman Consultant Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.